N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.83p
   
  • Change Today:
      0.025p
  • 52 Week High: 3.07
  • 52 Week Low: 0.75
  • Currency: UK Pounds
  • Shares Issued: 268.78m
  • Volume: 0
  • Market Cap: £2.22m

Deal with Barclays    Trade now with Barclays Stockbrokers

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
98.64% above the market average98.64% above the market average98.64% above the market average98.64% above the market average98.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Book Ratio
36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average36.75% below the market average
2.22% below the sector average2.22% below the sector average2.22% below the sector average2.22% below the sector average2.22% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
63.47% above the market average63.47% above the market average63.47% above the market average63.47% above the market average63.47% above the market average
48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average
Price Chg 3m
26.95% above the market average26.95% above the market average26.95% above the market average26.95% above the market average26.95% above the market average
37.04% above the sector average37.04% above the sector average37.04% above the sector average37.04% above the sector average37.04% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI Not Available
Momentum 20 Not Available

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
99.53% below the market average99.53% below the market average99.53% below the market average99.53% below the market average99.53% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
43.41% below the market average43.41% below the market average43.41% below the market average43.41% below the market average43.41% below the market average
36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
99.06% below the market average99.06% below the market average99.06% below the market average99.06% below the market average99.06% below the market average
93.94% below the sector average93.94% below the sector average93.94% below the sector average93.94% below the sector average93.94% below the sector average
Operating Profit Loss
46% below the market average46% below the market average46% below the market average46% below the market average46% below the market average
44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average44.00% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
82.65% below the market average82.65% below the market average82.65% below the market average82.65% below the market average82.65% below the market average
83.67% below the sector average83.67% below the sector average83.67% below the sector average83.67% below the sector average83.67% below the sector average
Cash
61.18% below the market average61.18% below the market average61.18% below the market average61.18% below the market average61.18% below the market average
72% below the sector average72% below the sector average72% below the sector average72% below the sector average72% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.83p
Change Today 0.025p
% Change 3.13 %
52 Week High 3.07
52 Week Low 0.75
Volume 0
Shares Issued 268.78m
Market Cap £2.22m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average
49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average
Value
32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average32.94% below the market average
49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page